70 filings
PRE 14A
SXTP
60 Degrees Pharmaceuticals Inc
3 May 24
Preliminary proxy
5:25pm
8-K
SXTP
60 Degrees Pharmaceuticals Inc
2 May 24
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
4:26pm
10-K
2023 FY
SXTP
60 Degrees Pharmaceuticals Inc
1 Apr 24
Annual report
2:32pm
8-K
SXTP
60 Degrees Pharmaceuticals Inc
14 Mar 24
Other Events
7:35pm
8-K
SXTP
60 Degrees Pharmaceuticals Inc
27 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:01pm
8-K
8o0j6wge xgl1ub3pq9b
20 Feb 24
Entry into a Material Definitive Agreement
4:00pm
8-K
j32dvp
2 Feb 24
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
12:00am
424B4
8pc0n
31 Jan 24
Prospectus supplement with pricing info
12:00am
EFFECT
kn4hj
30 Jan 24
Notice of effectiveness
12:15am
CORRESP
tze31wmfzq hgoruh
26 Jan 24
Correspondence with SEC
12:00am
CORRESP
04tavy934ka k0cvbs7
26 Jan 24
Correspondence with SEC
12:00am
CORRESP
vl59 6jeu
26 Jan 24
Correspondence with SEC
12:00am
8-K
ctlk lvgt1i
22 Jan 24
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
5:01pm
CORRESP
g7j819jezc5yc
22 Jan 24
Correspondence with SEC
12:00am
CORRESP
v64ezosy da
22 Jan 24
Correspondence with SEC
12:00am
UPLOAD
xtjw3ikw
18 Jan 24
Letter from SEC
12:00am
8-K
i81k5zcc0ze it6c6
16 Jan 24
Other Events
2:56pm
DRS
br3vsl
12 Jan 24
Draft registration statement
12:00am